SAVA - CASSAVA SCIENCES INC
IEX Last Trade
2.53
0 0%
Share volume: 19,493
Last Updated: Fri 27 Dec 2024 06:30:21 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.96%
PREVIOUS CLOSE
CHG
CHG%
$2.53
0.00
0.00%
Fundamental analysis
22%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
18%
Performance
5 Days
-2.90%
1 Month
-38.82%
3 Months
-92.66%
6 Months
-87.39%
1 Year
-89.98%
2 Year
-92.61%
Key data
Stock price
$2.53
DAY RANGE
$2.50 - $2.63
52 WEEK RANGE
$2.41 - $42.20
52 WEEK CHANGE
-$89.73
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Remi Barbier
Region: US
Website: cassavasciences.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cassavasciences.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial.
Recent news